Advertisement

Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence

  • N. García-Fernández
  • Hada C. Macher
  • Amalia Rubio
  • Pilar Jiménez-Arriscado
  • C. Bernal-Bellido
  • M. L. Bellido-Díaz
  • G. Suárez-Artacho
  • Juan M. Guerrero
  • M. A. Gómez-Bravo
  • Patrocinio Molinero
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 924)

Abstract

p53 is the most commonly mutated gene in malignant human cancers. To detect p53 mutations in circulating DNA (cirDNA) of transplanted hepatocellular carcinoma (HCC) patients could be an interesting approach to know of any tumor recurrence. In this study, our objective was to determine the utility of this method in the diagnosis and the prognosis of HCC tumor recurrence.

Twenty four liver transplanted HCC patients were included in the study together with a group of healthy controls. Detection of the specific p53 mutation in cirDNA was performed by high-resolution melting PCR (HRM-PCR) and COLD-PCR immediately before the transplantation. Serum anti-p53 was also determined using a p53-autoantibody ELISA kit.

The results of the HRM-PCR and COLD-PCR showed two well-differentiated groups of transplanted patients after normalization by healthy controls. These data allow us to distinguish between patients with p53 mutated cirDNA and those with wild type cirDNA. Moreover, we have found that most of p53 mutated patients also presented elevated anti-p53 antibodies. The present results indicate that it is possible to detect mutated p53 genes with the cirDNA and that this could be used as a biomarker of tumor recurrence during the clinical evolution of the transplanted patients.

Keywords

Circulating DNA p53 mutation Anti-p53 antibodies Hepatocellular carcinoma 

Notes

Conflict of Interest

No conflict of interest.

References

  1. Akere A, Otegbayo JA (2007) Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. Singap Med J 48(1):41–44Google Scholar
  2. Bernard L, Martha A, Thierry S (2014) P53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 35(6):672–688CrossRefGoogle Scholar
  3. Macher HC, Martinez-Broca MA, Rubio-Calvo A, Leon-Garcia C, Conde-Sanchez M, Costa A, Navarro E et al (2012) Non-invasive prenatal diagnosis of multiple endocrine neoplasia type 2A using COLD-PCR combined with HRM genotyping analysis from maternal serum. PLoS One 7(12):e51024CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • N. García-Fernández
    • 1
  • Hada C. Macher
    • 1
  • Amalia Rubio
    • 1
  • Pilar Jiménez-Arriscado
    • 1
  • C. Bernal-Bellido
    • 2
  • M. L. Bellido-Díaz
    • 1
  • G. Suárez-Artacho
    • 2
  • Juan M. Guerrero
    • 1
  • M. A. Gómez-Bravo
    • 2
  • Patrocinio Molinero
    • 1
  1. 1.Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville)University Hospital Virgen del Rocío of SevilleSevilleSpain
  2. 2.Hepatobiliary and Liver Transplantation UnitVirgen del Rocío University HospitalSevilleSpain

Personalised recommendations